SRR8518133
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.370
- G2M_CHECKPOINT+0.310
- SPERMATOGENESIS+0.260
- KRAS_SIGNALING_DN+0.170
- PANCREAS_BETA_CELLS+0.090
- MYOGENESIS+0.050
- OXIDATIVE_PHOSPHORYLATION+0.040
- MITOTIC_SPINDLE+0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- UV_RESPONSE_DN-0.390
- PROTEIN_SECRETION-0.380
- PI3K_AKT_MTOR_SIGNALING-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- ALLOGRAFT_REJECTION-0.300
- COMPLEMENT-0.300
- TGF_BETA_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.910 |
| 2 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.910 |
| 3 | BS_3V3KE3VT | medulloblastoma | — | 0.908 |
| 4 | SRR5088911 | — | — | 0.905 |
| 5 | C3L-00965 | — | cohortSQ2 | 0.900 |
| 6 | BS_W644VEVE | medulloblastoma | — | 0.898 |
| 7 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.892 |
| 8 | 20050169.TNBC | — | E | 0.892 |
| 9 | SRR8526719 | — | cohortMD1 | 0.892 |
| 10 | TCGA-B6-A402-01A-11R-A239-07 | — | E | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |